Zibdeh O, et al. - A prospective randomized study was undertaken to compare the clinical performance of the Carpentier–Edwards supra-annular valve (CE-SAV) (Edwards Lifesciences, Irvine, CA, USA) and the newer Mosaic (Medtronic Corporation, Minneapolis, MN, USA) porcine bioprostheses in the aortic position over a 10-year period. In this study, the CE-SAV group showed greater freedom from reoperation at 10 years after implantation. The Mosaic group showed fewer thromboembolisms and more paravalvular leaks. No other statistically significant differences were identified between CE-SAV and Mosaic aortic prostheses.